In the Phase 2 EMBOLD study of Progressive MS, ATA188 does not meet the primary end point.

Published Date: 12 Nov 2023

After receiving treatment for a year, the primary endpoint of the phase 2 EMBOLD study on ATA188, an allogenic T-cell immunotherapy, for non-active progressive multiple sclerosis, was not met.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

2.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

3.

Early detection of breast cancer may be possible with AI-based mammography microcalcification detection and classification.

4.

Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.

5.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot